The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Colchicine: An Ancient Drug with Modern Uses

Colchicine: An Ancient Drug with Modern Uses

August 11, 2021 • By Ibrahem Salloum, MD, & Deepan S. Dalal, MD, MPH

  • Tweet
  • Email
Print-Friendly Version / Save PDF

In 2019, there were two branded formulations of colchicine and generic colchicine was being manufactured by more than six companies, yet the unit cost was over $4.74. The cost of branded colchicine was $7.03.

You Might Also Like
  • FDA Enforcement Against Injectable Colchicine
  • Generic Colchicine Approved for Gout Prophylaxis
  • FDA Issues Boxed Warning for Febuxostat & Approves Colchicine for Gout Flare
Explore This Issue
September 2021

The unit cost of probenecid-colchicine over this entire study period remained at approximately $0.70.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

A total of 21 drugs received approvals from 2008–17 under the Unapproved Drugs Initiative, and two were granted exclusivity under the Orphan Drug Act. Eight of the 21 were self-administered agents, including morphine sulfate, oxycodone hydrochloride and atropine sulfate eye drops. Competition amongst manufacturers of these products was significantly reduced, and although not as remarkable as colchicine, several products saw an increase in unit price.30

In November 2020, the FDA decided to terminate the Unapproved Drug Initiative. In a report by the U.S. Department of Health and Human Services and the FDA, it stated several reasons for such an action. In addition to raising the costs of several drugs, including colchicine, the market exclusivity provided under the Unapproved Drugs Initiative created shortages of various drugs.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The report added that the majority of the drugs approved under this initiative were supported by literature reviews and bioequivalence to older drugs, with very little added in terms of new clinical trial evidence.

As a consequence, the cessation of this initiative will likely reduce the burden on American taxpayers and increase access to these drugs.35 It is presently unclear what will replace the Unapproved Drug Initiative.

Conclusion

Colchicine is one of the oldest remedies still in use today, with the potential for multiple indications. The anti-inflammatory and anti-fibrotic effects it confers, with a relatively favorable safety profile, make it an ideal drug for several rheumatic and non-rheumatic conditions. Although the cost of this very old drug remains inexplicably high, it is being investigated for several rheumatic and non-rheumatic conditions.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Ibrahem Salloum, MD, is a hospitalist and assistant professor (clinician-educator) with the Department of Medicine, Division of Hospital Medicine at the Warren Alpert School of Medicine, Brown University, Providence, R.I. He provides inpatient care at The Miriam Hospital in Providence and has an interest in caring for patients with rheumatic diseases.

Deepan S. Dalal, MD, MPH, has been a faculty member in the Department of Medicine, Rheumatology Section at the Warren Alpert School of Medicine for the past five years. He sees patients in the general rheumatology clinic at Brown Medicine Patient Center and has a special interest in musculoskeletal ultrasound. He focuses on health services and outcomes research and is particularly interested in geriatric patients suffering from inflammatory arthritis.

Pages: 1 2 3 4 5 6 7 | Single Page

Filed Under: Drug Updates Tagged With: anti­inflammatory, Colchicine, drug treatment, Gout, Gout Resource Center, inflammationIssue: September 2021

You Might Also Like:
  • FDA Enforcement Against Injectable Colchicine
  • Generic Colchicine Approved for Gout Prophylaxis
  • FDA Issues Boxed Warning for Febuxostat & Approves Colchicine for Gout Flare
  • Therapeutic Value of Colchicine in Osteoarthritis, Cardiovascular Disease Explored at the ACR/ARHP Winter Rheumatology Symposium

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)